{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T03:45:23Z","timestamp":1752551123908,"version":"3.40.1"},"reference-count":31,"publisher":"Ubiquity Press, Ltd.","issue":"1","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["gh"],"abstract":"<jats:p>Background: The World Health Organization recommends fixed-dose combination (FDC) pills for treating hypertension. Antihypertensive FDC pills often contain a renin-angiotensin inhibitor (RASI) or diuretic. Thus, screening and monitoring for dyskalemia (hypokalemia or hyperkalemia) before and after starting these classes of medications are recommended, a significant barrier for implementation in resource-limited settings. However, the need for blood tests may be overemphasized if the prevalence of dyskalemia in patients with hypertension is uncommon and the incidence of dyskalemia is rare after initiation of FDC.\nMethods: We conducted a community-based blood pressure (BP) screening program in Dhaka, Bangladesh, and determined the prevalence of dyskalemia, as defined by K &lt; 3.0 or K &gt; 5.5 mmol\/L, in untreated adults with SBP \u2265140 mmHg and\/or DBP \u226590 mmHg. Among those with a baseline serum K of \u22653.0 or \u22645.0 mmol\/L and creatinine clearance \u226530 ml\/min, we determined the incidence of dyskalemia 2 months after initiation of a daily FDC of telmisartan 40 mg and amlodipine 5 mg. Secondary outcomes were BP change, medication adherence, and symptoms.\nResults: In 2022\u20132023, we recruited 1,073 adults with SBP \u2265140 mmHg and\/or DBP \u226590 mmHg. The mean age was 54 years, with 71% men and mean baseline BP 157\/94 (SD 12\/9.3) mmHg. The prevalence of hypokalemia and hyperkalemia was 1.6% and 0.2%, respectively. FDC was initiated in 1,017 eligible patients, and 864 completed the 2-month follow-up visit. Incident hypokalemia occurred in 1.5% of patients, but there was no case of incident hyperkalemia. The mean change in serum potassium after initiating FDC was \u20130.05 (0.53) mmol\/L. At follow-up, 92% had BP &lt;140\/90 mmHg with a mean SBP change of \u201329.8 mmHg. 1% self-reported mild symptoms (e.g., leg swelling), and there was one death of undetermined cause.\nConclusions: Given low prevalence and incidence of hyperkalemia and evident reduction in BP, our study suggests initiating FDC with telmisartan and amlodipine may be a practical and safe option for newly diagnosed hypertension, especially in resource-constrained settings where blood tests cannot be easily obtained.<\/jats:p>","DOI":"10.5334\/gh.1415","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T09:39:13Z","timestamp":1742377153000},"page":"30","source":"Crossref","is-referenced-by-count":1,"title":["Dyskalemia Prior to and After Initiation of a Fixed Dose Combination of Telmisartan and Amlodipine in Adults with Hypertension in Bangladesh"],"prefix":"10.5334","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6396-3723","authenticated-orcid":false,"given":"Junichi","family":"Ishigami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Md. Mahmudul","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aruna","family":"Sarker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharmin","family":"Nahar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sibly Sadik","family":"Shuvo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mir","family":"Ishraquzzaman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Abdullah","family":"Al Mamun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Md.","family":"Kalimuddin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheikh Mohammad Mahbubus","family":"Sobhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiro","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence J.","family":"Appel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sohel Reza","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0157-6258","authenticated-orcid":false,"given":"Edgar R.","family":"Miller III","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fazila-Tun-Nesa","family":"Malik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3285","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"issue":"6","key":"key20250319093907_B1","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1161\/CIRCULATIONAHA.115.018912","article-title":"Global disparities of hypertension prevalence and control: A systematic analysis of population-based studies from 90 countries","volume":"134","year":"2016","journal-title":"Circulation"},{"issue":"10022","key":"key20250319093907_B2","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: A systematic review and meta-analysis","volume":"387","year":"2016","journal-title":"Lancet"},{"key":"key20250319093907_B3","article-title":"Combination therapy in the treatment of hypertension","volume":"7","year":"2018","journal-title":"Drugs in Context"},{"issue":"10150","key":"key20250319093907_B4","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(18)31814-2","article-title":"Fixed-dose combinations for hypertension","volume":"392","year":"2018","journal-title":"Lancet"},{"issue":"8","key":"key20250319093907_B5","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.amjmed.2006.08.033","article-title":"Fixed-dose combinations improve medication compliance: A meta-analysis","volume":"120","year":"2007","journal-title":"The American Journal of Medicine"},{"issue":"3","key":"key20250319093907_B6","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2215\/CJN.07821109","article-title":"Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors","volume":"5","year":"2010","journal-title":"Clinical Journal of the American Society of Nephrology (CJASN)"},{"issue":"11","key":"key20250319093907_B7","article-title":"Risk factors for non-communicable diseases in Bangladesh: Findings of the population-based cross-sectional national survey 2018","volume":"10","year":"2020","journal-title":"BMJ open"},{"key":"key20250319093907_B8","article-title":"Hypertension and undiagnosed hypertension among Bangladeshi adults: Identifying prevalence and associated factors using a nationwide survey","volume":"10","year":"2022","journal-title":"Frontiers in Public Health"},{"issue":"Suppl 3","key":"key20250319093907_B9","first-page":"iii17","article-title":"May Measurement Month 2021: An analysis of blood pressure screening results from Bangladesh","volume":"26","year":"2024","journal-title":"European Heart Journal Supplements"},{"issue":"3","key":"key20250319093907_B10","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/HJH.0000000000002682","article-title":"Simplified blood pressure measurement approaches and implications for hypertension screening: The Atherosclerosis Risk in Communities study","volume":"39","year":"2021","journal-title":"Journal of Hypertension"},{"key":"key20250319093907_B11","volume-title":"WHO model list of essential medicines, 21st List, 2019","author":"World Health Organization","year":"2019"},{"issue":"16","key":"key20250319093907_B12","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1001\/archinte.160.16.2429","article-title":"New guidelines for potassium replacement in clinical practice: A contemporary review by the National Council on Potassium in Clinical Practice","volume":"160","year":"2000","journal-title":"Archives of Internal Medicine"},{"issue":"6","key":"key20250319093907_B13","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMra035279","article-title":"Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system","volume":"351","year":"2004","journal-title":"The New England Journal of Medicine"},{"issue":"3","key":"key20250319093907_B14","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1177\/2047487313510678","article-title":"The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: Results from the ONTARGET trial","volume":"21","year":"2014","journal-title":"European Journal of Preventive Cardiology"},{"issue":"1","key":"key20250319093907_B15","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ahj.2004.03.020","article-title":"Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial\/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET\/TRANSCEND) trials","volume":"148","year":"2004","journal-title":"American Heart Journal"},{"issue":"9","key":"key20250319093907_B16","article-title":"Kidney function and potassium monitoring after initiation of renin-angiotensin-aldosterone system blockade therapy and outcomes in 2 North American populations","volume":"13","year":"2020","journal-title":"Circulation Cardiovascular Quality and Outcomes"},{"issue":"7","key":"key20250319093907_B17","article-title":"Hyperkalemia after initiating renin-angiotensin system blockade: The Stockholm Creatinine Measurements (SCREAM) Project","volume":"6","year":"2017","journal-title":"Journal of the American Heart Association"},{"issue":"5","key":"key20250319093907_B18","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1007\/s00394-023-03128-6","article-title":"Global mean potassium intake: A systematic review and Bayesian meta-analysis","volume":"62","year":"2023","journal-title":"European Journal of Nutrition"},{"issue":"25","key":"key20250319093907_B19","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1056\/NEJMoa1901113","article-title":"Comparison of dual therapies for lowering blood pressure in Black Africans","volume":"380","year":"2019","journal-title":"The New England Journal of Medicine"},{"issue":"7","key":"key20250319093907_B20","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1751-7176.2011.00468.x","article-title":"Telmisartan and amlodipine single-pill combinations vs amlodipine monotherapy for superior blood pressure lowering and improved tolerability in patients with uncontrolled hypertension: Results of the TEAMSTA-5 study","volume":"13","year":"2011","journal-title":"Journal of Clinical Hypertension"},{"issue":"10","key":"key20250319093907_B21","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1097\/HJH.0000000000000299","article-title":"Thiazides and the risk of hypokalemia in the general population","volume":"32","year":"2014","journal-title":"Journal of Hypertension"},{"key":"key20250319093907_B22","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ijcard.2017.12.026","article-title":"Is early and fast blood pressure control important in hypertension management?","volume":"254","year":"2018","journal-title":"International Journal of Cardiology"},{"issue":"9","key":"key20250319093907_B23","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1097\/HJH.0000000000002096","article-title":"Efficacy and safety of dual combination therapy of blood pressure-lowering drugs as initial treatment for hypertension: A systematic review and meta-analysis of randomized controlled trials","volume":"37","year":"2019","journal-title":"Journal of Hypertension"},{"issue":"1","key":"key20250319093907_B24","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/HJH.0000000000001977","article-title":"Regression to the mean of repeated ambulatory blood pressure monitoring in five studies","volume":"37","year":"2019","journal-title":"Journal of Hypertension"},{"issue":"Suppl 1","key":"key20250319093907_B25","first-page":"31","article-title":"Pharmacokinetics and pharmacodynamics of amlodipine","volume":"80","year":"1992","journal-title":"Cardiology"},{"key":"key20250319093907_B26","unstructured":"National Committee for Quality Assurance. Annual Monitoring for Patients on Persistent Medications (MPM) [Internet]. Washington, DC: National Committee for Quality Assurance; [cited 2023 Oct 31]. Available from: https:\/\/www.ncqa.org\/annual-monitoring-for-patients-on-persistent-medications\/."},{"issue":"1","key":"key20250319093907_B27","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/pds.1217","article-title":"Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers","volume":"16","year":"2007","journal-title":"Pharmacoepidemiology and Drug Safety"},{"issue":"7","key":"key20250319093907_B28","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2165\/11587250-000000000-00000","article-title":"Adherence to biochemical monitoring recommendations in patients starting with renin angiotensin system inhibitors: A retrospective cohort study in the Netherlands","volume":"34","year":"2011","journal-title":"Drug Safety"},{"issue":"6","key":"key20250319093907_B29","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1161\/HYPERTENSIONAHA.119.13749","article-title":"Potential of stratified medicine for high blood pressure management: A modeling study using NHANES survey data","volume":"74","year":"2019","journal-title":"Hypertension"},{"issue":"6","key":"key20250319093907_B30","doi-asserted-by":"crossref","first-page":"419","DOI":"10.7326\/M16-1754","article-title":"Benefits and harms of intensive blood pressure treatment in adults aged 60 years or older: A systematic review and meta-analysis","volume":"166","year":"2017","journal-title":"Annals of Internal Medicine"},{"issue":"16","key":"key20250319093907_B31","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1016\/j.jacc.2021.02.058","article-title":"Patient selection for intensive blood pressure management based on benefit and adverse events","volume":"77","year":"2021","journal-title":"Journal of the American College of Cardiology"}],"container-title":["Global Heart"],"original-title":[],"link":[{"URL":"https:\/\/account.globalheartjournal.com\/index.php\/up-j-gh\/article\/download\/1415\/1938","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/account.globalheartjournal.com\/index.php\/up-j-gh\/article\/download\/1415\/1939","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/account.globalheartjournal.com\/index.php\/up-j-gh\/article\/download\/1415\/1940","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/account.globalheartjournal.com\/index.php\/up-j-gh\/article\/download\/1415\/1938","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T09:47:17Z","timestamp":1742377637000},"score":1,"resource":{"primary":{"URL":"https:\/\/account.globalheartjournal.com\/index.php\/up-j-gh\/article\/view\/1415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,9]]}},"URL":"https:\/\/doi.org\/10.5334\/gh.1415","relation":{},"ISSN":["2211-8179","2211-8160"],"issn-type":[{"value":"2211-8179","type":"electronic"},{"value":"2211-8160","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,19]]}}}